Tag Archives: Cellectar Biosciences

Cellectar

Cellectar, Pierre Fabre Extend Relationship

Cellectar Biosciences has extended its collaboration with Pierre Fabre, a French pharmaceutical company, the company announced today. “The extension of our research agreement with Pierre Fabre allows us to further…

Cellectar

Cellectar, Onconova Therapeutics Collaborate

Cellectar Biosciences announced today it has entered into a strategic collaboration with Onconova Therapeutics, a biopharmaceutical company, to develop new phospholipid drug conjugates (PDC). According to a release, the Newtown,…

Cellectar

Cellectar’s Platform Shows Therapeutic Potential

Cellectar Biosciences‘ Phospholipid Drug Conjugate (PDC) research program has generated numerous PDC molecules that show “significant”¬†improved pharmacologic activity, the company announced today. According to a release, Cellectar’s research demonstrates that…

Cellectar

Cellectar Provides Myeloma Study Update

Cellectar Biosciences’ CLR 131 has achieved an overall survival of greater than 22 months in advanced multiple myeloma patients, the company announced today. “We continue to make meaningful progress on…

Cellectar

Cellectar Announces Swiss Collaboration

Cellectar Biosciences announced today that it will collaborate with Avicenna Oncology, a clinical stage biotechnology company based in Switzerland, to develop new phospholipid drug conjugates for solid tumors. According to…

Cellectar

Cellectar Adds Two to Board

Cellectar Biosciences added Douglas Swirsky and Frederick Driscoll to its board of directors, the company announced recently. Swirsky is the president and CEO of¬†GenVec and has worked at Stifel Nicolaus…

Cellectar

Cellectar to Begin Phase II Trial

Cellectar Biosciences announced today its initiation of a Phase II clinical study of CLR 131 in patients with multiple myeloma and other hemotologic malignancies. According to a release, the study…

Cellectar

Cellectar Earns Japanese Patent

Cellectar Biosciences announced today the Japanese Patent Office has granted a composition of matter patent for its optical imaging phospholipid drug conjugates (PDCs), CLR 1501 and CLR 1502. “This patent…

Cellectar

Cellectar, WARF Reach License Agreement

Cellectar Biosciences and the Wisconsin Alumni Research Foundation announced it new license agreement for intellectual property rights covering the method of use for the company’s compound, CLR 131, in multiple…

Cellectar

Cellectar Biosciences Receives Patent

The U.S. Patent and Trademark Office has awarded Cellectar Biosciences a patent that covers the method of use for CLR 1603 to treat breast, lung, colorectal and prostate cancers as…